Savara Q4 net loss widens as expenses rise

Savara

13/03/2026 12:15

Corrects first bullet of Result Drivers to clarify R&D expenses increased for the full year

Overview

US rare disease drug developer's Q4 net loss widened yr/yr as expenses rose

General and administrative expenses increased due to workforce expansion and commercial planning

Company achieved key regulatory milestones for MOLBREEVI in US and Europe

Outlook

Savara expects FDA PDUFA decision on MOLBREEVI by August 22, 2026

Result Drivers

REGULATORY COSTS - Full-year 2025 research and development expenses increased primarily due to regulatory affairs and quality assurance activities related to the MOLBREEVI BLA submission

COMMERCIAL PLANNING - General and administrative expenses rose due to workforce expansion and commercial activities ahead of potential MOLBREEVI launch

Company press release: ID:nBw2mblyra

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.13
Q4 Net Income
-$32.24 mln
Q4 Income from Operations
-$33.42 mln
Q4 Operating Expenses
$33.42 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Savara Inc is $10.25, about 92.7% above its March 12 closing price of $5.32

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)